Charles L Shapiro, MD Email Charles Shapiro
-
- Position
- PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialty
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Dubin Breast Center 212-241-3300212-241-3300
-
Dubin Breast Center
Dubin Breast Center
1176 Fifth Avenue, First Floor
New York, NY 10029
Phone: 212-241-3300212-241-3300
Professor of Medicine
Director of Translational Breast Cancer Research
Director of Cancer Survivorship, Tisch Cancer Institute
Division of Hematology/Medical Oncology Department of Medicine
Education
MD, S.U.N.Y, Buffalo - School of Med & Biomed Sciences
Internship, Internal Medicine
Temple University Hospital
Residency, Internal Medicine
Temple University Hospital
Fellowship, Medical Oncology
Beth Israel Deaconess Medical Center- Harvard Medical School
Language
English
2013
Physicians recognized for being in the top 10 percent for patient satisfaction, nationally
2005
America's Top Doctors for Cancer
2005
Bertha Bouroncle Teaching Award
2001
America's Top Doctors
1998
Best Doctors in America
1991
American Cancer Society Clinical Oncology Career Development
American Cancer Society
The James Champion Award
James Cancer Hospital
Bacilli Award for Academic Excellence
University of Buffalo Medical School
John Watson Award for Scholarship in Medicine
University of Buffalo Medical School
Alpha Omega Alpha
New topic
The focus of my research is investigator-initiated early phase clinical trials in breast cancer. Areas of interest include: breast cancer survivorship, in particular the impact and treatment of adjuvant chemotherapy-induced bone loss in premenopausal women; microRNA profiling of triple negative breast cancers to define subsets that have better or worse prognosis; and preclinical evaluations of novel drugs in collaboration with a medicinal chemist, including a PDK-1 inhibitor, AMP kinase inhibitor and the PARP inhibitors. At Mount Sinai I plan to form collaborations with laboratory-based scientists to evaluate novel drugs preclinically, develop investigator-initiated trials to further define subsets of triple negative breast cancers using genomic methods, and to conduct investigator-initiated trials in breast cancer survivorship.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Shapiro has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.